MetLife (MET)
NYSEFinancialsInsurance - LifeSnapshot 2026-11-04
$102.89+2.21%
Close 2026-11-04 · 1-day change
NYSEFinancialsInsurance - LifeSnapshot 2026-11-04
Research Workspace
Put MET beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 9% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskMetLife's double-digit earnings growth has to keep compounding to justify the price. Revenue grew 12% year over year in the latest quarter. The company beat its earnings estimate by 2.6%. It trades at 2.4 times book value versus a 1.3 times peer median. The price reflects less growth than we forecast. Management is running behind on a stated commitment. Peer multiples imply a price about 50% above where it trades (it looks cheap on this basis). The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. MET is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering MET (as of Nov 2026).
Based on 8 Wall Street analysts offering 12-month price targets for MET in the last 4 months.
Continue this research
Compare MET with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MET Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life & Health Insurance — fair value, gap to price, and forward P/E.
Compare the value case
Put MET next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Deliver double-digit adjusted earnings per share growth
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $102.89
The last 12 months of price, then the range of analyst 12-month targets from today’s $102.89.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Guidance above midpoint supports double-digit EPS growth objective.
Advances: Deliver double-digit adjusted earnings per share growth
Strong sales support double-digit EPS growth target.
Potential acquisition aligns with growth and revenue objectives.
Acquisition supports growth and capital allocation objectives.
Advances: Deliver double-digit adjusted earnings per share growth
Growth plan aligns with EPS growth objective.
Advances: Maintain disciplined capital allocation and return capital to shareholders
Buyback supports capital allocation and shareholder returns.
Economic concerns may impact premium growth and overall revenues.
Advances: Maintain disciplined capital allocation and return capital to shareholders
Share repurchase supports disciplined capital allocation and shareholder returns.